Cartesian Therapeutics Forecast, price target & analysts
Cartesian Therapeutics Target price 2025 - Analyst rating & recommendation
Cartesian Therapeutics Classifications & Recommendation:
Cartesian Therapeutics Price Target
| Target Price | $40.80 |
| Price | $9.01 |
| Potential |
352.83%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Cartesian Therapeutics 2026 .
The average Cartesian Therapeutics target price is $40.80.
This is
352.83%
register free of charge
$44.10
389.46%
register free of charge
$16.16
79.36%
register free of charge
|
|
| A rating was issued by 15 analysts: 12 Analysts recommend Cartesian Therapeutics to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cartesian Therapeutics stock has an average upside potential 2026 of
352.83%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 38.91 | 1.87 |
| 49.65% | 95.20% | |
| Net Margin | -198.97% | -2,845.77% |
| 76.45% | 1,330.24% |
11 Analysts have issued a sales forecast Cartesian Therapeutics 2025 . The average Cartesian Therapeutics sales estimate is
This results in the following potential growth metrics:
11 Cartesian Therapeutics Analysts have issued a net profit forecast 2025. The average Cartesian Therapeutics net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.48 | -2.05 |
| 89.46% | 54.24% | |
| P/E | negative | |
| EV/Sales | 39.57 |
11 Analysts have issued a Cartesian Therapeutics forecast for earnings per share. The average Cartesian Therapeutics EPS is
This results in the following potential growth metrics and future valuations:
Cartesian Therapeutics...
Current Cartesian Therapeutics Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wedbush |
Locked
➜
Locked
|
Locked | Jul 09 2025 |
| Needham |
Locked
➜
Locked
|
Locked | May 08 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wedbush:
Locked
➜
Locked
|
Jul 09 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 09 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Apr 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Mar 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 28 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
